Previous 10 | Next 10 |
Gainers: Bio-Path Holdings (BPTH) +253%.Cancer Genetics (CGIX) +74%.Torchlight Energy Resources (TRCH) +73%.CM Life Sciences (CMLF) +51%.India Globalization Capital (IGC) +42%.Anchiano Therapeutics (ANCN) +42%.The OLB Group (OLB) +41%.Sundial Growers (SNDL) +40%.Clever Lea...
Bio-Path shares skyrocket ([[BPTH]] +213.5%) after it announces that the United States Patent and Trademark Office has granted the company U.S. Patent No. 10,898,506 titled, "P-ethoxy nucleic acids for liposomal formulation".The new patent builds on earlier patents granted that...
Cancer Genetics (CGIX) +131%.The OLB Group (OLB) +83% on plan to offer Cryptocurrency payment options via blockchain technology.BioHiTech Global (BHTG) +66%.Bio-Path Holdings (BPTH) +50%.Neptune Wellness Solutions (NEPT) +48% on acquisition of organic baby food maker Sprout Foods.Ga...
HOUSTON, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize ® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that the Unite...
Bio-Path Holdings (BPTH) enrolls the first patient in a Phase 1 clinical trial evaluating the ability of BP1002 to treat refractory/relapsed lymphoma and chronic lymphocytic leukemia ((CLL)) patients. A total of six evaluable patients will be treated with BP1002 monotherapy in a standard...
HOUSTON, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced the enrollment an...
Bio-Path Holdings, Inc. (BPTH) Q3 2020 Earnings Conference Call November 13, 2020 8:30 AM ET Company Participants Will O’Connor – Stern Investor Relations Peter Nielsen – President and Chief Executive Officer Anthony Price – Senior Vice President-Finance, Accountin...
HOUSTON, Nov. 13, 2020 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced its financial res...
Bio-Path (BPTH): Q3 GAAP EPS of -$0.80 beats by $0.07.Cash of $12.1MPress Release For further details see: Bio-Path EPS beats by $0.07
HOUSTON, Nov. 06, 2020 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize ® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host ...
News, Short Squeeze, Breakout and More Instantly...
Bio-Path Holdings Inc. Company Name:
BPTH Stock Symbol:
NASDAQ Market:
Bio-Path Holdings Inc. Website:
Marks Meaningful Progress Across Key Clinical Trials in Multiple Cancer Indications Completes Development of Oncology Molecular Biomarkers and Prepares for Preclinical Obesity Studies HOUSTON, July 08, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnolog...
2024-06-17 10:10:00 ET June 17, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the first of a two-part series looking at developments for the treatment of blood cancers. Today's snapshot focuses in on acute myeloid leukemia (AML) and the compan...